Search results for "TOR Serine-Threonine Kinases"

showing 10 items of 78 documents

mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA

2013

Abstract Vaccination with in vitro transcribed RNA encoding tumor antigens is an emerging approach in cancer immunotherapy. Attempting to further improve RNA vaccine efficacy, we have explored combining RNA with immunomodulators such as rapamycin. Rapamycin, the inhibitor of mTOR, was used originally for immunosuppression. Recent reports in mouse systems, however, suggest that mTOR inhibition may enhance the formation and differentiation of the memory CD8+ T-cell pool. Because memory T-cell formation is critical to the outcome of vaccination aproaches, we studied the impact of rapamycin on the in vivo primed RNA vaccine-induced immune response using the chicken ovalbumin-expressing B16 mela…

Cancer Researchmedicine.medical_treatmentImmunologyMelanoma ExperimentalCD8-Positive T-LymphocytesBiologyCancer VaccinesLymphocytes Tumor-InfiltratingImmune systemAntigenCancer immunotherapyAntigens NeoplasmIn vivomedicineAnimalsRNA NeoplasmPI3K/AKT/mTOR pathwaySirolimusVaccines SyntheticAntibiotics AntineoplasticTOR Serine-Threonine KinasesVaccinationRNACell DifferentiationCombined Modality TherapyMice Inbred C57BLVaccinationImmunologyCancer researchFemaleDrug Screening Assays AntitumorImmunologic MemoryCD8Cancer Immunology Research
researchProduct

Cannabinoid receptor 1 modulates the autophagic flux independent of mTOR- and BECLIN1-complex

2013

Cannabinoid Receptor 1 (CB1) has been initially described as the receptor for Delta-9-Tetrahydrocannabinol in the central nervous system (CNS), mediating retrograde synaptic signaling of the endocannabinoid system. Beside its expression in various CNS regions, CB1 is ubiquituous in peripheral tissues, where it mediates, among other activities, the cell's energy homeostasis. We sought to examine the role of CB1 in the context of the evolutionarily conserved autophagic machinery, a main constituent of the regulation of the intracellular energy status. Manipulating CB1 by siRNA knockdown in mammalian cells caused an elevated autophagic flux, while the expression of autophagy-related genes rema…

Cannabinoid receptorMorpholinesGreen Fluorescent ProteinsDown-RegulationmTORC1NaphthalenesBiochemistryMiceCellular and Molecular NeurosciencePiperidinesReceptor Cannabinoid CB1RimonabantAutophagymedicineAnimalsHumansEnzyme InhibitorsCannabinoid Receptor AntagonistsCells CulturedPI3K/AKT/mTOR pathwayAdenine NucleotidesChemistryTOR Serine-Threonine KinasesAutophagyMembrane ProteinsCalcium Channel BlockersEmbryo MammalianEndocannabinoid systemBenzoxazinesCell biologyMice Inbred C57BLnervous systemAstrocytesPyrazolesBeclin-1lipids (amino acids peptides and proteins)MacrolidesSynaptic signalingRimonabantApoptosis Regulatory ProteinsFlux (metabolism)medicine.drugJournal of Neurochemistry
researchProduct

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

2019

Introduction: Carfilzomib (Cfz) correlates with a risk of reversible cardiotoxicity in 5-10% of multiple myeloma (MM) patients. We have recently shown that metformin (Met) has a prophylactic role against the Cfz-induced cardiotoxicity in vivo, through activation of AMPKα signaling (Blood 2019;133:710-23). However, the impact of Cfz on vascular function is obscure. Therefore, we sought to investigate: i) the acute, ii) the sub-chronic effect of Cfz on the vascular reactivity, iii) the effect of metformin co-administration on the vascular phenotype and iv) the impact of Cfz and Met co-administration on aged Human Aortic Smooth Muscle Cells (HAoSMCs). Methods: Forty male C57Bl/6 mice were assi…

CardiotoxicityMulticatalytic endopeptidase complexbusiness.industryMTOR Serine-Threonine KinasesImmunologyAutophagyCell BiologyHematologyBiochemistryCarfilzomibAngiotensin IIMetforminchemistry.chemical_compoundchemistryAnimals laboratoryCancer researchmedicinebusinessmedicine.drugBlood
researchProduct

Polycystin-1 downregulation induces ERK-dependent mTOR pathway activation in a cellular model of psoriasis

2018

Psoriatic plaques tend to localize to the knees and elbows, areas that are particularly subject to mechanical stress resulting from bending and friction. Moreover, plaques often develop at sites of mechanical trauma or injury (Koebner phenomenon). Nevertheless, mechanotransduction has never been linked to psoriasis. Polycystins (polycystin-1, PC1; polycystin-2, PC2) are mechanosensitive molecules that function as key regulators of cellular mechanosensitivity and mechanotransduction. The aim of this in vitro study was to investigate the role of polycystins in the development of psoriasis. We showed that PC1 knockdown in HaCaT cells led to an elevated mRNA expression of psoriasis-related biom…

Genetic Markers0301 basic medicineMAPK/ERK pathwayendocrine systemTRPP Cation ChannelsMAP Kinase Signaling SystemDown-RegulationModels BiologicalCell Line03 medical and health sciences0302 clinical medicineDownregulation and upregulationCell MovementPsoriasismedicineHumansPsoriasisMechanotransductionMolecular BiologyPI3K/AKT/mTOR pathwayCell ProliferationGene knockdownCell growthChemistryTOR Serine-Threonine Kinasesmedicine.diseaseCell biologyHaCaT030104 developmental biologyGene Knockdown Techniques030220 oncology & carcinogenesisMolecular MedicineBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Interventions to Slow Aging in Humans: Are We Ready?

2015

The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?' was held in Erice, Italy, on October 8-13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consens…

GerontologyAgingDisease onsetPrescription DrugsLongevityPsychological interventionReviewsBiologyAMP-Activated Protein KinasesGrowth hormoneAging; Anti-aging; Centenarians; Dietary restriction; Lifespan studies; Longevity gene; Longevity regulation; Cell Biology; AgingDietary interventionsBiological FactorsMicelongevity geneSettore BIO/13 - Biologia ApplicataAnimalsHumansSirtuinsProtein restrictionCentenarianInsulin-Like Growth Factor ILifespan studieCaloric RestrictionSettore MED/04 - Patologia GeneraleGeroscienceGene targetsRibosomal Protein S6 KinasesTOR Serine-Threonine Kinasesanti-agingdietary restrictionCell Biologydietary restriction ; lifespan studies ; longevity gene ; centenarians ; anti-aging ; longevity regulation ; aginglongevity regulation3. Good healthDietEnzyme ActivationGene Expression RegulationGrowth HormoneGenetics of agingcentenariansaging; anti-aging; centenarians; dietary restriction; lifespan studies; longevity gene; longevity regulationSignal Transductionlifespan studies
researchProduct

The loss of muscle mass and sarcopenia: non hormonal intervention.

2011

Muscle aging is a key component of the increase in frailty in human populations. The generation of critical levels of power is a prerequisite to perform simple tasks of daily living, such as rising from a chair or climbing stairs. There is great scientific and social interest to determine which behaviors can lead to the maintenance of the muscle mass in young immobilized subjects and in the elderly. Several hormonal treatments have been proposed for the treatment of sarcopenia. However, the side effects associated to these treatments emphasize the need of finding non-toxic and non-hormonal treatments that help increase muscle strength, improve muscle function, and decrease the degree of dep…

Gerontologymedicine.medical_specialtyAgingSarcopeniaNon hormonalFrail ElderlyPopulationLongevityMuscle massBiochemistryBenzoatesLosartanAngiotensin Receptor AntagonistsEndocrinologyPhysical medicine and rehabilitationIntervention (counseling)GeneticsmedicineAnimalsHumansMuscle StrengthPPAR deltaTelmisartaneducationMolecular BiologyExerciseHeat-Shock ProteinsAgedAged 80 and overeducation.field_of_studybusiness.industryPublic healthTOR Serine-Threonine KinasesCell Biologymedicine.diseasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMuscle atrophyMuscular AtrophySarcopeniaMuscle strengthBenzimidazolesmedicine.symptombusinesshuman activitiesTranscription FactorsExperimental gerontology
researchProduct

Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients

2016

Appropriate post-transplant immunosuppressive regimens that avoid acute rejection, while reducing risk of viral reactivation, have been sought, but remain a chimera. Recent evidence suggesting potential regulatory and antiviral effects of mammalian target of rapamycin inhibitors (mTORi) is of great interest. Although the concept of an immunosuppressive drug with antiviral properties is not new, little effort has been made to put the evidence together to assess the management of immunosuppressive therapy in the presence of a viral infection. This review was developed to gather the evidence on antiviral activity of the mTORi against the viruses that most commonly reactivate in adult solid org…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentHepatitis C virus030230 surgerymedicine.disease_causeAntiviral AgentsOrgan transplantationVirus03 medical and health sciencesChimera (genetics)0302 clinical medicinemedicineHumansImmunosuppression TherapyTransplantationEverolimusbusiness.industryTOR Serine-Threonine Kinasesvirus diseasesImmunosuppressionOrgan TransplantationTransplant RecipientsInfectious DiseasesImmunosuppressive drugVirus DiseasesSirolimusImmunology030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugTransplant Infectious Disease
researchProduct

Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment

2021

Mutations affecting mTOR or RAS signaling underlie defined syndromes (the so-called mTORopathies and RASopathies) with high risk for Autism Spectrum Disorder (ASD). These syndromes show a broad variety of somatic phenotypes including cancers, skin abnormalities, heart disease and facial dysmorphisms. Less well studied are the neuropsychiatric symptoms such as ASD. Here, we assess the relevance of these signalopathies in ASD reviewing genetic, human cell model, rodent studies and clinical trials. We conclude that signalopathies have an increased liability for ASD and that, in particular, ASD individuals with dysmorphic features and intellectual disability (ID) have a higher chance for disrup…

Heart diseaseAutism Spectrum DisorderReviewQH426-47003 medical and health sciencesEpilepsy0302 clinical medicineIntellectual disabilitymedicineGeneticsAnimalsHumansGene Regulatory NetworksGenetics (clinical)PI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesbusiness.industryTOR Serine-Threonine KinasesCancermedicine.diseasePhenotype3. Good healthClinical trialDisease Models AnimalGene Expression RegulationAutism spectrum disorderintellectual disabilityMutationras ProteinsmTORbusinessNeuroscience030217 neurology & neurosurgerySignal TransductionRASGenes
researchProduct

Clinical and molecular data in cases of prenatal localized overgrowth disorder: major implication of genetic variants in PI3K‐AKT‐mTOR signaling path…

2021

To describe clinical and molecular findings in a French multicenter cohort of fetuses with prenatal diagnosis of congenital abnormality and suspicion of a localized overgrowth disorder (LOD) suggestive of genetic variants in the PI3K-AKT-mTOR signaling pathway.We analyzed retrospectively data obtained between 1 January 2013 and 1 May 2020 from fetuses with brain and/or limb overgrowth referred for molecular diagnosis of PI3K-AKT-mTOR pathway genes by next-generation sequencing (NGS) using pathological tissue obtained by fetal autopsy. We also assessed the diagnostic yield of amniotic fluid.During the study period, 21 subjects with LOD suspected of being secondary to a genetic variant of the…

HemimegalencephalyPathologymedicine.medical_specialtyGenetic counselingPrenatal diagnosisGermlineAKT3Phosphatidylinositol 3-KinasesHumansMedicineRadiology Nuclear Medicine and imagingMegalencephalyPI3K/AKT/mTOR pathwayRetrospective StudiesFetusRadiological and Ultrasound Technologybusiness.industryTOR Serine-Threonine KinasesObstetrics and GynecologyGeneral Medicinemedicine.diseaseReproductive MedicineMutationbusinessProto-Oncogene Proteins c-aktSignal TransductionUltrasound in Obstetrics & Gynecology
researchProduct

Inflammatory Characteristics of Monocytes from Pediatric Patients with Tuberous Sclerosis.

2015

Objective  Therapeutic options for the tuberous sclerosis complex (TSC) syndrome showed varying outcomes. Malfunctional tsc1 / tsc2 genes leave mTOR uninhibited, a positive downstream modulator of the innate proinflammatory immune system, which has not yet been described in pediatric patients with TSC. Methods  Using polymerase chain reaction (PCR) gene expression levels of monocytes after cultivation with lipopolysaccharide (LPS) or with LPS + mTOR inhibitor rapamycin, patients with TSC ( n  = 16) were compared with healthy subjects ( n  = 20). Results  Compared with monocytes from healthy controls, LPS showed a more prominent gene expression pattern in patients with TSC (CCL24, CXCL10, IL…

Lipopolysaccharidescongenital hereditary and neonatal diseases and abnormalitiesLipopolysaccharideGene ExpressionMonocytesProinflammatory cytokinechemistry.chemical_compoundTuberous sclerosisTuberous SclerosisGene expressionmedicineCXCL10HumansChildInflammationSirolimusbusiness.industryTOR Serine-Threonine KinasesInfant NewbornInfantGeneral Medicinemedicine.diseasemedicine.anatomical_structureCross-Sectional StudieschemistryChild PreschoolPediatrics Perinatology and Child HealthImmunologyCytokinesNeurology (clinical)TSC1TSC2Inflammation MediatorsbusinessCCL24Immunosuppressive AgentsNeuropediatrics
researchProduct